14
Views
1
CrossRef citations to date
0
Altmetric
REVIEW

Radioimmunotherapeutic approaches for leukemia: the past, present and future

, PhD , MD
Pages 13-20 | Published online: 07 Jul 2009
 

Abstract

For more than a decade, Ab conjugated to a radionuclide emitting particulate radiation has been used in the management of leukemia in an effort to deliver targeted doses of radiation to BM, spleen and other sites of disease, while sparing normal organs. This radioimmunotherapy (RIT) approach has been employed to achieve significant remissions in patients with AML, particularly when used at high doses of radioactivity in conjunction with myeloablation. This report focuses on the therapeutic aspects of radiolabeled Ab for leukemia. Clinical results from recent leukemia RIT studies are reviewed, with emphasis on approaches being evaluated to improve rates of response and survival. Discussion of pre-clinical studies are limited to those that offer insights into future directions for clinical RIT studies of leukemia.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.